Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Swen Hoelder(Institute of Cancer Research), Paul Workman(Institute of Cancer Research)
Cited by 581
Related Papers
Guidelines for the welfare and use of animals in cancer research
|British Journal of Cancer|2010|1.4k
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
|British Journal of Cancer|2005|513
New approaches to molecular cancer therapeutics
|Nature Chemical Biology|2006|387
The Cyclin-dependent Kinase Inhibitor CYC202 (<b><i>R</i></b>-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway
|Cancer Research|2004|194
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
|Current Medicinal Chemistry|2011|103